Core Viewpoint - Sirius Therapeutics-B has submitted a listing application to the Hong Kong Stock Exchange, aiming to leverage its proprietary siRNA technology platform to address unmet medical needs in chronic diseases [1] Company Overview - Sirius Therapeutics-B is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [1] - The company is backed by a strategic foundation that includes three potential blockbuster product pipelines, a proprietary siRNA technology platform, and a global collaboration network [1] Strategic Goals - The company aims to innovate the current treatment standards for chronic diseases by developing first-in-class and best-in-class siRNA therapies targeting significant unmet medical needs globally [1]
Sirius Therapeutics（ 靖因药业）递表港交所
Xin Lang Cai Jing·2025-09-28 12:20